| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.064 | 0.1 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | -0.049 | 0.1 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.054 | 0.1 |